ASTRO: Siemens unveils Accela radiotherapy system
Siemens Healthineers stock climbed to EUR 41.21 after RBC Capital Markets raised its price target to EUR 48 and confirmed an outperform rating following the launch of the Accela radiotherapy system. RBC analysts highlighted the new treatment platform as a key driver for the German medical technology company. Conversely, Oddo BHF cut its price target for Siemens Healthineers to EUR 45, and the company discontinued the distribution of several ultrasound models. The Accela system features NeoArc Dynamic Modulated Arc Therapy and is heading to Australia via GenesisCare, though it awaits United States 510(k) sales clearance after debuting in Boston.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ RBC Capital Markets raised its price target for Siemens Healthineers to EUR 48 and confirmed an outperform rating following the launch of the Accela radiotherapy system.
- ✓ Siemens Healthineers shares rose 1.0% to EUR 41.21.
- ✓ Oddo BHF cut its price target for Siemens Healthineers to EUR 45.
What changed
Financial analysts adjusted their targets for Siemens Healthineers, with RBC raising its target to EUR 48 and Oddo BHF lowering its target to EUR 45 following the Accela launch.
Live updates
-
Siemens Shares Rise as RBC Boosts Target on Accela
Siemens Healthineers stock climbed to EUR 41.21 after RBC Capital Markets raised its price target to EUR 48 and confirmed an outperform rating following the launch of the Accela radiotherapy system. RBC analysts highlighted the new treatment platform as a key driver for the German medical technology company. Conversely, Oddo BHF cut its price target for Siemens Healthineers to EUR 45, and the company discontinued the distribution of several ultrasound models. The Accela system features NeoArc Dynamic Modulated Arc Therapy and is heading to Australia via GenesisCare, though it awaits United States 510(k) sales clearance after debuting in Boston.
Why it matters
The launch of the Accela radiotherapy platform has directly impacted market sentiment for Siemens Healthineers, prompting split reactions from financial analysts. While RBC raised its target based on the potential of the new cancer treatment device, Oddo BHF lowered its target amid adjustments to the company product line that included retreating from ultrasound models. The system itself aims to deliver rapid multi-site stereotactic body radiation therapy.
What is confirmed
- RBC Capital Markets raised its price target for Siemens Healthineers to EUR 48 and confirmed an outperform rating following the launch of the Accela radiotherapy system.
- Siemens Healthineers shares rose 1.0% to EUR 41.21.
- Oddo BHF cut its price target for Siemens Healthineers to EUR 45.
Still unconfirmed
- Siemens Healthineers discontinued the distribution of several ultrasound models.
What to watch next
- U.S. 510(k) regulatory clearance decision for the Accela radiotherapy system
- Market performance of Siemens Healthineers shares following the EUR 48 target set by RBC and EUR 45 target set by Oddo BHF
- Deployment and clinical results of the Accela platform through GenesisCare in Australia
confidence 95%Sources used for this update (6)
- www.ad-hoc-news.de — Siemens Healthineers Rallies as RBC Backs Accela Launch, Oddo ...
- www.marketscreener.com — RBC Ups Siemens Healthineers Price Target After Accela Launch
- sectra.com — News and press releases - Sectra Group
- www.zonebourse.com — RBC relève l’objectif de cours de Siemens Healthineers après ...
- www.stock-world.de — Siemens Healthineers Aktie: Die Accela-Hoffnung?
- www.sharedeals.de — Siemens Healthineers-Aktie: Sind jetzt 48 € drin?
-
GenesisCare to deploy Siemens Accela radiotherapy system in Australia
GenesisCare is introducing the Accela radiotherapy platform to Australia to advance cancer treatment technology. The Siemens Healthineers system utilizes NeoArc Dynamic Modulated Arc Therapy to combine high precision with fast treatment speeds. The platform enables scalable stereotactic treatments, including multi-site stereotactic body radiation therapy that can be delivered in 60 seconds during one breath-hold. While the system debuted at the American Society for Radiation Oncology Annual Meeting in Boston, it remains pending U.S. 510(k) clearance for sales. RBC analysts recently raised their price target for Siemens Healthineers to EUR 48 following the launch.
Why it matters
The Accela platform targets the high-precision radiation oncology market. Its deployment in Australia represents an early international rollout of the technology. Financial analysts are monitoring the system's impact on Siemens Healthineers' revenue and portfolio.
What is confirmed
- GenesisCare will bring the Accela radiotherapy platform to Australia.
- The Accela system is based on NeoArc Dynamic Modulated Arc Therapy.
- The American Society for Radiation Oncology Annual Meeting took place September 26 to 30 in Boston.
- RBC raised its Siemens Healthineers price target to EUR 48.
Still unconfirmed
- Berenberg downgraded Siemens Healthineers to Hold with a 39-euro target.
What to watch next
- U.S. 510(k) clearance for Accela sales
- Further international adoption announcements beyond Australia
confidence 95%Sources used for this update (11)
- kprofiles.com — ASTRO Members Profile (Updated!) - Kpop Profiles
- www.genesiscare.com — GenesisCare to bring next-generation Accela radiotherapy ...
- radiologiemagazin.de — Neue Generation der Strahlentherapie - RadMag - Online ...
- www.cancernetwork.com — American Society for Radiation Oncology Annual Meeting (ASTRO)
- www.ad-hoc-news.de — Siemens Healthineers Stuck at Berenberg's New 39-Euro Target ...
- www.ad-hoc-news.de — Siemens Healthineers Wins First ENERGY STAR Nod for an MRI ...
- www.j-mdc.com — Medical Device News and Press Releases|Japan MDC, LLC
- www.ad-hoc-news.de — Siemens Healthineers Wins RBC Upgrade on Accela Launch as ...
- article.wn.com — GenesisCare to bring next-generation Accela radiotherapy ...
- www.healthday.com — ASTRO 2026: Advances in Radiation Oncology and Cancer Research
- carlaperna.co.uk — What’s New in Prostate Cancer Radiotherapy: ASTRO 2026
-
Siemens Healthineers unveils Accela radiotherapy system
Siemens Healthineers has launched its Accela radiotherapy platform, enabling scalable stereotactic treatments, including multi-site stereotactic body radiation therapy that can be delivered in as little as 60 seconds during a single breath-hold. The system was revealed at ASTRO 2026 and is pending U.S. 510(k) clearance for sales. RBC analysts expect the platform to increase revenue for Siemens Healthineers.
Why it matters
The Accela radiotherapy system is a significant development in the field of radiation therapy, offering faster and more efficient treatment options for patients. The launch of this platform is expected to have a positive impact on Siemens Healthineers' revenue. The company's stock performance has been mixed, with analysts split ahead of its Q4 results.
What is confirmed
- Siemens Healthineers launched its Accela radiotherapy platform at ASTRO 2026.
- The Accela radiotherapy system enables scalable stereotactic treatments, including multi-site stereotactic body radiation therapy that can be delivered in as little as 60 seconds during a single breath-hold.
- The Accela radiotherapy system is pending U.S. 510(k) clearance for sales.
- RBC analysts expect the Accela platform to increase revenue for Siemens Healthineers.
Still unconfirmed
- Analysts are split on Siemens Healthineers' stock ahead of its Q4 results.
What to watch next
- U.S. 510(k) clearance for Accela radiotherapy system
- Siemens Healthineers' Q4 results
- Accela radiotherapy system's impact on Siemens Healthineers' revenue
confidence 100%Sources used for this update (3)
- www.ad-hoc-news.de — Siemens Healthineers Courts Lab Diagnostics and Radiotherapy ...
- oncodaily.com — Read News and Stories about ASTRO 2026 - Oncodaily
- www.infranken.de — Siemens Healthineers stellt Technologiesprung vor – "Beginn ...
-
Siemens Healthineers unveils Accela radiotherapy system
Siemens Healthineers has launched its Accela radiotherapy platform, which enables scalable stereotactic treatments, including multi-site stereotactic body radiation therapy that can be delivered in as little as 60 seconds during a single breath-hold. The system was revealed at ASTRO 2026 and is pending U.S. 510(k) clearance for sales. RBC analysts expect the platform to increase revenue for Siemens Healthineers.
Why it matters
The Accela platform is designed to increase speed and precision for various cancer cases. It uses NeoArc and has a validated adaptive quality assurance solution from Sun Nuclear. The launch of Accela brings new technology to the field of radiotherapy.
What is confirmed
- Siemens Healthineers launched Accela at ASTRO 2026.
- Accela enables scalable stereotactic treatments, including multi-site stereotactic body radiation therapy that can be delivered in as little as 60 seconds during a single breath-hold.
- Accela uses NeoArc to increase speed and precision for various cancer cases.
- The system requires U.S. 510(k) clearance before any sales.
Still unconfirmed
- RBC analysts expect the platform to increase revenue for Siemens Healthineers
What to watch next
- U.S. 510(k) clearance for Accela
- installation of Accela at Radiochirurgia Zagreb in November
- Siemens Healthineers stock performance
confidence 100%Sources used for this update (3)
- www.ad-hoc-news.de — Siemens Healthineers' 60-Second Radiotherapy Push Meets a ...
- www.ad-hoc-news.de — Siemens Healthineers launches Accela and reports buyback of ...
- saudedigitalnews.com.br — Siemens Healthineers lança solução de radioterapia Accela
-
Radiochirurgia Zagreb to install Siemens Accela radiotherapy system
Radiochirurgia Zagreb will begin installing the Siemens Healthineers Accela radiotherapy system in November. This brings the new technology to Croatia. The Accela platform enables scalable stereotactic treatments, including multi-site stereotactic body radiation therapy, which can be delivered in as little as 60 seconds during a single breath-hold. The system uses NeoArc to increase speed and precision for various cancer cases, while Sun Nuclear provides a validated adaptive quality assurance solution. RBC analysts expect the platform to increase revenue for Siemens Healthineers.
Why it matters
The system debuted at the ASTRO 2026 meeting. High-speed delivery reduces the time patients must remain still during radiation. This deployment marks the initial expansion of the technology into the Croatian market.
What is confirmed
- The Accela platform can deliver multi-site SBRT in as little as 60 seconds during a single breath-hold.
- Siemens Healthineers developed the Accela system using NeoArc to combine speed and precision.
Still unconfirmed
- Radiochirurgia Zagreb will begin installing the Accela system in November.
What to watch next
- Confirmation of the first patient treatment in Croatia
- Additional hospital installation announcements outside of Croatia
confidence 90%Sources used for this update (4)
- www.hospitalsandhealthcare.com — Siemens Healthineers launches Accela radiotherapy platform
- www.croatiaweek.com — New cancer treatment technology coming to Croatia
- quadshotnews.com — Accela – QuadShot
- www.distillintelligence.com — Latest Siemens Healthineers News & Announcements
-
Siemens Healthineers Unveils Ultrafast Accela Radiotherapy System
Siemens Healthineers has launched Accela, an ultrafast radiotherapy system designed to deliver high-speed stereotactic treatments and multi-site stereotactic body radiation therapy in as little as 60 seconds during a single breath-hold. Unveiled at the ASTRO 2026 meeting, the platform is engineered around NeoArc to combine speed and precision across a broad range of cancer cases. In support of the launch, Sun Nuclear announced a validated adaptive quality assurance solution for the new system. Financial analysts at RBC note that the radiation therapy platform launch is positioned to drive revenue for Siemens Healthineers.
Why it matters
The introduction of the Accela platform marks a significant push in medical technology toward reducing the time patients spend in radiotherapy treatment while scaling complex procedures. Systems capable of treating multiple areas in fractions of a minute address critical bottlenecks in oncology departments. Concurrently, software validation by partners like Sun Nuclear ensures that rapid delivery methods maintain necessary safety standards.
What is confirmed
- Siemens Healthineers launched the Accela radiotherapy system at ASTRO 2026.
- The Accela platform can deliver stereotactic treatments and multi-site SBRT in as little as 60 seconds in a single breath-hold.
- Sun Nuclear announced a validated adaptive QA solution to support the new Accela system.
- RBC stated that the radiation therapy platform launch is expected to drive revenue for Siemens Healthineers.
What to watch next
- Adoption rates and clinical deployment outcomes of the Accela system in oncology centers.
- Financial impact reports on revenue growth following the platform launch as tracked by RBC and market analysts.
confidence 100%Sources used for this update (22)
- ny1.com — Mayor Mamdani unveils executive budget proposal, says city's budget deficit has been closed
- www.astro.com — Astrodienst - The World's Best Horoscopes
- AuntMinnie — ASTRO: Siemens unveils Accela radiotherapy system
- Siemens Healthineers — The Future of Radiology is Here: Siemens Healthineers Launches Accela
- Business Wire — Sun Nuclear Announces Validated Adaptive QA Solution in Support of New Radiotherapy System, Accela, by Siemens Healthineers
- The Manila Times — The Future of Radiotherapy is Here: Siemens Healthineers Launches Accela
- marketscreener.com — Siemens Healthineers' Upcoming Radiation Therapy Platform Launch to Drive Revenue, RBC Says
- World Business Outlook — Sun Nuclear Validates Adaptive QA Solution for Siemens Healthineers’ New Accela System
- Stock Titan — A new radiation system can treat multiple areas in as little as 60 seconds. Siemens Healthineers calls it Accela.
- physicsworld.com — Siemens Healthineers unveils ultrafast Accela radiotherapy system – Physics World
- astro.build — Astro
- www.astro.com — All free horoscopes at Astrodienst
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community